International Journal of Clinical Oncology

, Volume 17, Issue 4, pp 399–406

Extraosseous Ewing’s sarcoma of the pancreas

Authors

    • Hematology/Oncology Division, Department of Internal MedicineUniversity of Oklahoma Health Sciences Center
    • Hematology/Oncology Division, Department of Internal MedicineVirginia Commonwealth University/Massey Cancer Center
  • Paari Murugan
    • Department of PathologyUniversity of Oklahoma Health Sciences Center
  • Elizabeth Gillies
    • Department of PathologyUniversity of Oklahoma Health Sciences Center
  • Jennifer L. Holter
    • Hematology/Oncology Division, Department of Internal MedicineUniversity of Oklahoma Health Sciences Center
Case Report

DOI: 10.1007/s10147-011-0311-6

Cite this article as:
Bose, P., Murugan, P., Gillies, E. et al. Int J Clin Oncol (2012) 17: 399. doi:10.1007/s10147-011-0311-6

Abstract

The Ewing’s family of tumors (EFT) comprises a molecularly defined group of “small round blue cell tumors”, consisting of Ewing’s sarcoma of bone (ESB), extraosseous Ewing’s sarcoma (EES), peripheral primitive neuroectodermal tumor (pPNET), and Askin’s tumor. Characteristic translocations that disrupt the EWSR1 gene located at 22q12 create novel fusion genes that are central to the pathogenesis. The EFT also shares certain clinical characteristics, such as a peak incidence during the teenage years, a tendency to spread rapidly, and responsiveness to the same chemotherapeutic regimens and radiation therapy. Nearly all patients have occult disseminated disease at diagnosis; hence, chemotherapy is routinely used. Improvements in multimodality treatment have had a dramatic impact on outcomes. EES/pPNET has been reported in a variety of sites, including the pancreas, though this is extremely rare. We describe a case of pancreatic EES/pPNET in a 35-year-old woman and provide a brief review of the relevant literature.

Keywords

Ewing’s sarcomaExtraosseous Ewing’s sarcomaPrimitive neuroectodermal tumorPNETPancreas

Copyright information

© Japan Society of Clinical Oncology 2011